{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorder&page=84", "query": { "condition": "Skin Disorder", "page": 84 }, "page_size": 10 }, "pagination": { "page": 84, "page_size": 10, "total_count": 16135, "total_pages": 1614, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorder&page=85&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorder&page=83&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T04:25:02.658Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05003310", "title": "ConsideRAte Study - Splenic Stimulation for RA", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Active Stimulation", "type": "DEVICE" }, { "name": "Sham Stimulation", "type": "DEVICE" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Background Treatment", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Galvani Bioelectronics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "22 Years to 75 Years" }, "enrollment_count": 28, "start_date": "2021-10-19", "completion_date": "2032-04", "has_results": false, "last_update_posted_date": "2024-05-22", "last_synced_at": "2026-11-07T04:25:02.658Z", "location_count": 12, "location_summary": "Anniston, Alabama • Covina, California • Whittier, California + 8 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Covina", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Hagerstown", "state": "Maryland" }, { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05003310" }, { "nct_id": "NCT00835510", "title": "Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tinea Pedis" ], "interventions": [ { "name": "Butenafine cream 1% manufactured by Taro", "type": "DRUG" }, { "name": "Lotrimin Ultra (butenafine) 1%", "type": "DRUG" }, { "name": "Butenafine Vehicle manufactured by Taro", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 548, "start_date": "2008-06", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2014-02-04", "last_synced_at": "2026-11-07T04:25:02.658Z", "location_count": 16, "location_summary": "Burbank, California • San Diego, California • Miami, Florida + 13 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Martinez", "state": "Georgia" }, { "city": "Stockbridge", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00835510" }, { "nct_id": "NCT00891020", "title": "A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "tocilizumab [RoActemra/Actemra]", "type": "DRUG" }, { "name": "Nonbiologic DMARDs of investigator's choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 886, "start_date": "2009-05", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2012-10-25", "last_synced_at": "2026-11-07T04:25:02.658Z", "location_count": 227, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 201 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00891020" }, { "nct_id": "NCT01708382", "title": "Feasibility Study: Lifting and Tightening of the Elbows", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Skin Laxity" ], "interventions": [ { "name": "Ulthera System Treatment", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Ulthera, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 21, "start_date": "2011-09", "completion_date": "2013-02", "has_results": false, "last_update_posted_date": "2017-11-24", "last_synced_at": "2026-11-07T04:25:02.658Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01708382" }, { "nct_id": "NCT03621982", "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer Squamous Cell Carcinoma", "Non-small Cell Lung Cancer", "Gastric Cancer", "Esophageal Cancer", "Pancreas Cancer", "Bladder Cancer", "Renal Cell Carcinoma", "Melanoma", "Triple-negative Breast Cancer", "Ovarian Cancer", "Colo-rectal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "ADCT-301", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "ADC Therapeutics S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2018-11-09", "completion_date": "2022-12-14", "has_results": true, "last_update_posted_date": "2024-06-13", "last_synced_at": "2026-11-07T04:25:02.658Z", "location_count": 5, "location_summary": "Palo Alto, California • New Haven, Connecticut • Portland, Oregon + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03621982" }, { "nct_id": "NCT07743723", "title": "A Study of IOV-5001 in Adults With Advanced Solid Tumors", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Non-Small Cell Lung Cancer", "Triple Negative Breast Cancer (TNBC)", "Colorectal Cancer", "Head and Neck Squamous Cell Carcinoma", "Metastatic Solid Tumors", "Unresectable Solid Tumor" ], "interventions": [ { "name": "IOV-5001", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 106, "start_date": "2026-09", "completion_date": "2044-03", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-11-07T04:25:02.658Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07743723" }, { "nct_id": "NCT01724580", "title": "Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)", "Juvenile Dermatomyositis (JDM)", "Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)", "Aicardi-Goutières Syndrome (AGS)" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": null, "sex": "ALL", "summary": "6 Months and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-11-07T04:25:02.658Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01724580" }, { "nct_id": "NCT03406962", "title": "MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Inherited Metabolic Disorders (IMD)" ], "interventions": [ { "name": "MGTA-456", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Magenta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "0 Years to 17 Years" }, "enrollment_count": 8, "start_date": "2018-02-09", "completion_date": "2021-01-15", "has_results": true, "last_update_posted_date": "2021-11-03", "last_synced_at": "2026-11-07T04:25:02.658Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Cincinnati, Ohio", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03406962" }, { "nct_id": "NCT01433978", "title": "A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Idiopathic Thrombocytopenic Purpura" ], "interventions": [ { "name": "Eltrombopag", "type": "DRUG" }, { "name": "Avatrombopag", "type": "DRUG" }, { "name": "Standard of care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 24, "start_date": "2012-03-26", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2018-02-06", "last_synced_at": "2026-11-07T04:25:02.658Z", "location_count": 1, "location_summary": "Watertown, South Dakota", "locations": [ { "city": "Watertown", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01433978" }, { "nct_id": "NCT04531540", "title": "Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypersensitivity" ], "interventions": [ { "name": "Butenafine HCl 1% (BAY1896425)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 225, "start_date": "2013-09-09", "completion_date": "2013-10-18", "has_results": true, "last_update_posted_date": "2020-11-17", "last_synced_at": "2026-11-07T04:25:02.658Z", "location_count": 1, "location_summary": "Fairfield, New Jersey", "locations": [ { "city": "Fairfield", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04531540" } ] }